Aim: To investigate the efficacy of surgery combined with post-operative trancatheter arterial chemoembolization (TACE) for intermediate hepatocellular carcinoma (HCC).
Methods: A total of 102 patients were divided into two groups: Radical liver resection only (LR group, 52 patients) and radical liver resection combined with post-operative TACE (combined group, 50 patients). Survival analysis was performed using the Kaplan–Meier method. Univariate and multivariate analysis were performed using Cox proportional analysis to detect prognostic factors of survival outcomes.
Results: The 1-, 3- and 5-year survival rate in the LR group were significantly lower compared with those in combined group (p?=?.019). The 1-, 3- and 5-year progression-free survival rate in the LR group were also lower than those in the combined group (p?=?.048). Multivariate analysis detected that tumor number (multiple vs single), tumor distribution (both lobes vs semi-liver), treatment strategy (surgery?+?TACE vs surgery) were independent factors for OS (HR values were 2.307, 3.155 and 0.526, respectively) and PFS (HR values were 1.938, 3.425 and 0.633, respectively; p?<?.05).
Conclusion: In conclusion, surgery combined with post-operative TACE may improve survival outcomes for patients with intermediate HCC. Tumor number, tumor distribution and treatment strategy (surgery?+?TACE) were significantly associated with the prognosis of patients with intermediate HCC. 相似文献
目的:观察125 I放射性粒子联合经肝动脉化疗栓塞(trans catheter arterial ehemoembolization,TACE)治疗原发性肝癌的临床疗效及安全性。方法:选取2010—09—12—2012—08—26广西医科大学附属肿瘤医院的原发性肝癌患者53例,其中行125 I放射性粒子联合TACE治疗的27例患者作为治疗组,单纯行TACE治疗的26例患者作为对照组,观察2组患者的中位疾病进展时间(median time to progression,mTTP),并分析有效率(responserate,RR)、疾病控制率(disease control rate,DCR)及安全性。结果:治疗组与对照组mTTP分别为8.3和5.7个月,差异有统计学意义,P=0.020;中位生存时间分别为11.2和8.5个月,差异有统计学意义,P=0.010。125 I放射性粒子植入后2个月,治疗组与对照组RR分别为70.4%(19/27)和26.9%(7/26),差异有统计学意义,P=0.002;DCR分别为81.5%(22/27)和53.8%(14/26),差异有统计学意义,P=0.042。2组患者均未发生严重不良反应。结论:125 I放射性粒子联合TACE治疗原发性肝癌可延长患者的mTTP,并可提高RR及DCR,且安全性较好。 相似文献